Viridian Therapeutics Q3 2026 earnings
Revenue from Lumvoa launch begins, but losses widen as SG&A increases and R&D remains high.
Headline numbers
not stated in the 8-K
Revenue breakdown
not stated in the 8-K
Margins and costs
- Gross margin 94.1% (prior 0%, change +94.1 pp)
- Operating expenses $129.2M (+16.9% YoY)
- One-offs in the quarter not stated in the 8-K
- Effective tax rate 0% (prior-year 0%, year-to-date 0%)
- Non-GAAP bridge No reconciliation provided.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Lumvoa net product revenue | $24.7M | $0 | $0 | +$24.7M |
| Patients on therapy | 100+ | 0 | 0 | 100+ |
Guidance
not stated in the 8-K
What drove it
- Revenue story Product revenue of $24.7M from Lumvoa launch; total revenues of $25.8M, down 63.4% YoY due to a 64% drop in license revenue.
- EPS story Loss per share widened to -$0.81 due to higher operating expenses and a larger share count.
- One-off check None stated.
The good
- Lumvoa net product revenue of $24.7M
- 100+ patients on therapy
The bad
- Net loss widened to $101.2M
- SG&A increased to $57.6M (+136.7% YoY)
- Cash balance declined to $955.2M
The ugly
- none
Open questions
- What caused the 136.7% YoY increase in Selling, General and Administrative expenses?
- Why did License revenue drop from $70,000 to $125 in Q3 2026?
Full release
Viridian Therapeutics (VRDN) earnings release, November 4, 2026
Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress
- $24.7 million in Lumvoa™
(veligrotug-vvze) net product revenue with more than 100 patients on therapy at the end of Q3 2026 -
- Elegrobart Biologics License Application (BLA) submission on track for Q1 2027 -
-
VRDN-008 phase 1 data disclosure on track for Q4 2026 -
-
VRDN-292, a potential best-in-class
TSHR inhibitor, expected to initiate a phase 1 clinical trial in patients in Q4 2026 -
- Cash, cash equivalents, and marketable securities of $955.2 million as of September 30, 2026 -
- Company to host webcast today, November 4, at 8:00 a.m. ET -
WALTHAM, Mass. – Nov. 4, 2026—Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported financial results and recent business updates for the third quarter ended September 30, 2026.
“We are highly encouraged by the strength of Lumvoa’s early launch in TED, which has exceeded expectations,” said Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics. “These strong early results are a testament to Lumvoa’s compelling clinical profile, the extraordinary execution of our Commercial and Medical teams, and the incredible support of our broader organization. We are excited about this early momentum and look forward to building on it as we continue to execute our launch strategy and strive to bring Lumvoa to more patients with
TED. Our pipeline also continues to move forward as we advance elegrobart, our subcutaneously administered anti-IGF-1R, toward a planned BLA submission for TED in the first quarter of 2027. In addition, we look forward to several important milestones for the remainder of this year, including sharing clinical data for
VRDN-008, development plans for our FcRn portfolio, and initiating a first-in-human clinical trial in patients for our TSHR program
VRDN-292.”
Recent Business Highlights
THYROID EYE DISEASE
TSHR PROGRAM
FCRN PORTFOLIO
Financial Results
Conference Call and Webcast Information
Viridian will host a conference call and webcast today, November 4, at 8:00 a.m. ET to discuss third quarter 2026 financial results and recent business updates. The dial-in number for the conference call is +1
833-461-5787 for domestic participants and +1
585-542-9983 for international participants. The conference ID is 599668655.
A live webcast of the conference call can be accessed under “Events & Presentations” on the Investors section of the Viridian website at viridiantherapeutics.com. Following the live webcast, an archived version of the call will also be available on the Viridian website.
Upcoming Investor Conferences
Viridian will participate in the following upcoming investor conferences. Live webcasts of the presentations can be accessed under “Events & Presentations” on the Investors section of the Viridian website at viridiantherapeutics.com. Replays of the webcasts will be available following each event on the Viridian website.
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company dedicated to developing better medicines for patients with autoimmune and rare diseases. Utilizing our expertise in antibody discovery and protein engineering, we aim to build on proven science to develop innovative medicines that address unmet needs and improve patient outcomes.
With an immediate focus in thyroid eye disease (TED), we developed Lumvoa
TM, a full
IGF-1R antagonist approved by the U.S. FDA for the treatment of thyroid eye disease. We are also advancing elegrobart, a late-stage investigational subcutaneous therapy designed to further address unmet needs in TED and improve patient convenience. Beyond TED, we are advancing a pipeline of potential best-in-class medicines to address multiple serious autoimmune diseases.
Viridian is based in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com. Follow Viridian on
LinkedIn and
X.
Forward Looking Statements
Financial statements
Income Statement
Three Months Ended September 30, — (Unaudited) (in thousands)
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|---|---|
| Revenues: | ||||
| Product revenue, net | 24,671 | $— | 24,671 | $— |
| License revenue | 125 | 70,000 | 364 | 70,000 |
| Collaboration revenue - related parties | 956 | 570 | 1,142 | 717 |
| Total revenues | 25,752 | 70,570 | 26,177 | 70,717 |
| Operating expenses: | ||||
| Cost of revenues | 1,527 | 1,527 | ||
| Research and development | 70,093 | 86,261 | 219,301 | 249,721 |
| Selling, general and administrative | 57,609 | 24,322 | 151,263 | 61,642 |
| Total operating expenses | 129,229 | 110,583 | 372,091 | 311,363 |
| Loss from operations | -103,477 | -40,013 | -345,914 | -240,646 |
| Total other income, net | 2,268 | 5,414 | 12,685 | 18,400 |
| Net loss | -101,209 | -34,599 | -333,229 | -222,246 |
| Net loss allocated to common stock | -91,444 | -28,169 | -296,528 | -180,856 |
| Net loss per share, basic and diluted, common stock | -0.81 | -0.34 | -2.75 | -2.22 |
| Weighted-average common shares outstanding, basic and diluted | 113,407,432 | 81,784,499 | 107,875,408 | 81,576,987 |
| Net loss allocated to Series A convertible preferred stock | -7,160 | -3,097 | -24,605 | -19,934 |
| Net loss per share, basic and diluted, Series A convertible preferred stock | -53.76 | -22.96 | -183.26 | -147.81 |
| Weighted-average Series A convertible preferred stock outstanding, basic and diluted | 133,191 | 134,864 | 134,263 | 134,864 |
| Net loss allocated to Series B convertible preferred stock | -2,605 | -3,333 | -12,096 | -21,456 |
| Net loss per share, basic and diluted, Series B convertible preferred stock | -53.76 | -22.96 | -183.26 | -147.81 |
| Weighted-average Series B convertible preferred stock outstanding, basic and diluted | 48,463 | 145,160 | 66,004 | 145,160 |
Balance Sheet
September 30, 2026 — (Unaudited) (in thousands)
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| Cash, cash equivalents, and marketable securities | 955,206 | 874,652 |
| Accounts receivable, net | 29,782 | |
| Other assets | 43,682 | 24,766 |
| Total assets | 1,028,670 | 899,418 |
| Total liabilities | 447,972 | 177,251 |
| Total stockholders’ equity | 580,698 | 722,167 |
| Total liabilities and stockholders’ equity | 1,028,670 | 899,418 |
Cash Flow
From the 10-Q · Nine Months Ended September 30, — (Unaudited)
| Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | -333,229 | -222,246 |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Share-based compensation expense | 47,606 | 32,314 |
| Non-cash interest expense | 13,486 | 308 |
| Depreciation and amortization | 581 | 340 |
| Accretion and amortization of available-for-sale securities | -4,864 | -5,005 |
This press release contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “become,” “continue,”
“could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “on track,” “plan,” “potential,” “predict,”
“project,” “should,” “target,” “will,” or “would” or other similar terms or expressions that concern our expectations, plans and intentions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. Forward-looking statements include, without limitation, statements regarding: that the company’s current commercial and medical affairs infrastructure will support an elegrobart launch; preclinical development, clinical development, and anticipated commercialization of Viridian’s product candidates, including the company’s intention to communicate development plan updates for Viridian’s FcRn portfolio in Q4 2026 and plans to initiate a phase 1 clinical trial for
VRDN-292 in Q4 2026; anticipated data results and timing of their disclosure, including
VRDN-008 phase 1 healthy volunteer data expected in Q4 2026; Viridian’s expectations regarding the anticipated timing or likelihood of regulatory submissions and approvals, including a BLA submission for elegrobart in the first quarter of 2027; elegrobart’s potential to be a subcutaneous therapy for the treatment of
TED with Q4W and Q8W dosing; Viridian’s product candidates potentially being best-in-class;
Viridian’s... (truncated)rket opportunities of veligrotug and elegrobart, if approved; and that Viridian’s cash and anticipated commercial revenues from Lumvoa and, if approved, elegrobart, will be sufficient to fund its business plans through profitability.
New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to: that the company has historically incurred losses and may not be able to secure additional capital when needed; that the company has a limited history of generating revenue from product sales; that the company may be unable to maintain commercial manufacturing, sales and marketing capabilities or enter into agreements with third parties to commercially manufacture, market and sell veligrotug; market acceptance of veligrotug; potential utility, efficacy, potency, safety, clinical benefits, clinical response, and convenience of veligrotug and Viridian’s product candidates; that results or data from completed or ongoing clinical trials may not be representative of the results of ongoing or future clinical trials; that preliminary data may not be representative of final data; the timing, progress and plans for ongoing or future research, preclinical, and clinical development programs; changes to trial protocols for ongoing or new clinical trials; expectations and changes regarding the timing for regulatory filings; regulatory interactions; expectations and changes regarding the timing for enrollment and data; uncertainty and potential delays related to clinical drug development; the duration and impact of regulatory delays in Viridian’s clinical programs; the timing of and Viridian’s ability to obtain and maintain regulatory approvals for its therapeutic candidates; manufacturing risks; competition from other therapies or products; estimates of market size and market opportunity; other matters that could affect the sufficiency of existing cash, cash equivalents, and short-term investments to fund operations; Viridian’s financial position; Viridian’s future operating results and financial performance; Viridian’s intellectual property position; the timing of preclinical and clinical trial activities and reporting results from same; that Viridian’s product candidates may not be commercially successful, if approved; and other risks described from time to time in the “Risk Factors” section of our filings with the Securities and Exchange Commission, including those described in our most recent Annual Report on Form
10-K or Quarterly Report on Form
10-Q, as applicable, and supplemented from time to time by our Current Reports on Form
8-K.
Any forward-looking statement speaks only as of the date on which it was made. Neither the company, nor its affiliates, advisors, or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date hereof.
Viridian Therapeutics, Inc.
Condensed Consolidated Statements Of Operations
(In thousands, except share and per share data)
(Unaudited)
Viridian Therapeutics, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)
Contacts
Investors
Greg Rossino grossino@viridiantherapeutics.com
Media
Lisa Lopez llopez@viridiantherapeutics.com
Source: Viridian Therapeutics,
Inc.